ArticleSAGE open medical case reports2025
Atopic dermatitis associated with systemic tacrolimus: Case report and review.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 10-month-old female was referred to dermatology clinic for evaluation of eczema, noted at 110 days after deceased-donor liver transplant while receiving systemic tacrolimus as monotherapy for posttransplant immunosuppression. She was seen and diagnosed with new onset atopic dermatitis (AD), thought to be in part related to her tacrolimus. After failing conventional treatment, her immunosuppression was switched from tacrolimus to sirolimus, and she received 1 dose of dupilumab. After 1 month, her skin had considerably improved and further doses of dupilumab were not pursued. At last follow-up, her eczema had completely cleared. Although infrequently reported in the literature, there is a growing body of evidence to suggest systemic tacrolimus may induce AD in transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.